Short Interest in Chimerix, Inc. (NASDAQ:CMRX) Declines By 10.6%

Chimerix, Inc. (NASDAQ:CMRX) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,690,000 shares, a drop of 10.6% from the July 31st total of 1,890,000 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily trading volume, of 485,300 shares, the short-interest ratio is presently 3.5 days.

Analysts Set New Price Targets

A number of research analysts have commented on CMRX shares. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Wedbush reaffirmed an “outperform” rating and set a $6.00 target price on shares of Chimerix in a report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday, August 14th.

Chimerix Stock Performance

Shares of Chimerix stock traded down $0.07 on Tuesday, reaching $0.87. 538,480 shares of the company were exchanged, compared to its average volume of 405,400. The company’s 50-day moving average is $0.90 and its two-hundred day moving average is $0.97. The firm has a market cap of $77.69 million, a price-to-earnings ratio of -0.98 and a beta of 1.20. Chimerix has a 1-year low of $0.75 and a 1-year high of $1.30.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. Chimerix had a negative return on equity of 46.35% and a negative net margin of 25,337.96%. During the same period in the prior year, the firm earned ($0.21) EPS. As a group, sell-side analysts forecast that Chimerix will post -0.86 earnings per share for the current year.

Institutional Trading of Chimerix

Institutional investors and hedge funds have recently made changes to their positions in the stock. Koshinski Asset Management Inc. acquired a new stake in shares of Chimerix during the 1st quarter worth approximately $42,000. Marquette Asset Management LLC increased its position in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares during the period. Marshall Wace LLP acquired a new stake in Chimerix in the 2nd quarter valued at approximately $137,000. Pale Fire Capital SE increased its position in Chimerix by 113.6% in the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 112,318 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in Chimerix in the 4th quarter valued at approximately $1,348,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.